Top of this page
Skip navigation, go straight to the content

ucb-usa.com Newsroom UCB U.S. News

Categories

  • Advancing Our Green Strategy for the Future

    Posted by Katelyn Snider, U.S. Communications and Public Affairs
    Green_Day_Plant_in_Test_Tube
    We believe our ability to continue to innovate and create value for patients now and in the future will increasingly depend on our positive contributions to environmental sustainability.

    Read more

  • Press Release: UCB to provide additional information to the U.S. FDA regarding midazolam nasal spray submission

    UCB_LOGO_1280x960


    Brussels (Belgium) & Atlanta, Georgia (U.S.) - April 1, 2019:
    UCB announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter requesting additional information to complete the review of the New Drug Application for midazolam nasal spray, a rescue treatment for acute repetitive seizures (ARS, also known as seizure clusters) in patients with epilepsy. UCB acquired the rights to midazolam nasal spray from Proximagen in June 2018.

    Read more